{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:58:13Z","timestamp":1770814693051,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtct.2021.07.015","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T03:05:58Z","timestamp":1626750358000},"page":"863.e1-863.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Cole H.","family":"Sterling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Holdhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian B.","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Abbas","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan M.","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip H.","family":"Imus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.07.015_bib0001","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0003","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2021.07.015_bib0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/10428190802311458","article-title":"Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment","volume":"49","author":"van Besien","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.07.015_bib0005","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1083-8791(00)70060-7","article-title":"High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma","volume":"6","author":"Alvarnas","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.015_bib0006","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3324\/haematol.2012.070839","article-title":"Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation\u2014an international Primary Central Nervous System Lymphoma Study Group project","volume":"98","author":"Bromberg","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.07.015_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-3-319-13150-4_14","article-title":"Allogeneic hematopoietic cell transplantation in non-Hodgkin's lymphomas","volume":"165","author":"Aldoss","year":"2015","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.jtct.2021.07.015_bib0008","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pi\u00f1ana JL","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.07.015_bib0009","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.015_bib0010","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.015_bib0011","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.015_bib0013","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.015_bib0014","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study","volume":"91","author":"Rigacci","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.015_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)?","volume":"28","author":"Galea","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0017","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0306-4522(94)00448-E","article-title":"Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette-Gu\u00e9rin","volume":"64","author":"Matyszak","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.jtct.2021.07.015_bib0018","first-page":"58","article-title":"Immunity to homologous grafted skin. III. The fate of skin homographs transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye","volume":"29","author":"Medawar","year":"1948","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0019","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nri3265","article-title":"The anatomical and cellular basis of immune surveillance in the central nervous system","volume":"12","author":"Ransohoff","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2021.07.015_bib0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08830185.2017.1357719","article-title":"CNS: Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ","volume":"37","author":"Negi","year":"2018","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0022","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.015_bib0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2018.02.001","article-title":"Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: is it feasible?","volume":"12","author":"Atilla","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2021.07.015_bib0024","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10428199909083396","article-title":"Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma","volume":"34","author":"Varadi","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.07.015_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0026","doi-asserted-by":"crossref","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.","DOI":"10.1200\/JCO.2005.13.524"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2021.07.015_bib0027","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.4081\/pr.2011.s2.e15","article-title":"Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide","volume":"3","author":"Munchel","year":"2011","journal-title":"Pediatr Rep"},{"key":"10.1016\/j.jtct.2021.07.015_bib0028","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.07.015_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbmt.2004.09.009","article-title":"High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.07.015_bib0030","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/bjh.12451","article-title":"Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement","volume":"162","author":"Maziarz","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","article-title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","volume":"93","author":"El-Galaly","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2021.07.015_bib0032","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3324\/haematol.2015.126110","article-title":"Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network","volume":"100","author":"Damaj","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.07.015_bib0033","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas","volume":"98","author":"Korfel A","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2021.07.015_bib0034","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.07.015_bib0035","doi-asserted-by":"crossref","unstructured":"Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18:76-83.","DOI":"10.1016\/j.bbmt.2011.07.006"},{"key":"10.1016\/j.jtct.2021.07.015_bib0036","doi-asserted-by":"crossref","unstructured":"Qualls D, Sullivan A, Li S, et al. High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement. Clin Lymphoma Myeloma Leuk. 2017;17:884-888.","DOI":"10.1016\/j.clml.2017.08.100"},{"key":"10.1016\/j.jtct.2021.07.015_bib0037","doi-asserted-by":"crossref","unstructured":"Scordo M, Bhatt V, Hsu M, et al. A comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2017;23:38-43.","DOI":"10.1016\/j.bbmt.2016.09.024"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:05:19Z","timestamp":1763003119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721010800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666636721010800"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.07.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}